Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound.

BACKGROUND: To determine the accuracy of contrast-enhanced ultrasonography (CEUS) in differentiating malignant and benign venous thrombosis complicating hepatocellular carcinoma (HCC). METHODS: Fifty patients (M:F = 41:9; age range 46-83 years) with HCC and venous thrombosis [portal vein (PV) in 45 and hepatic vein (HV) in 5] detected on CT or MR scan were evaluated with CEUS. Reference standard of malignant and benign thrombosis was based on serial clinicoradiologic follow-up (n = 43) or pathology (n = 7). Two independent, blinded readers retrospectively recorded the enhancement features of the venous thrombosis and diagnosed as benign or malignant thrombosis with a five-point confidence scale. Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic performance of CEUS in differentiating malignant from benign thrombosis. Confidence level ratings were also used to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the diagnosis of malignant thrombosis. Inter-reader agreement was calculated using κ statistics in each assessed finding. Gray scale and Doppler characteristics of primary tumor and thrombosis were also assessed. RESULTS: Of the 50 patients, 37 were malignant (33 with PV thrombosis and 4 with HV thrombosis) and 13 were benign (12 with PV thrombosis and 1 with HV thrombosis). In ROC curve analysis for differentiating malignant from benign thrombosis, Az was 0.947 (CI 0.841-0.991) for reader 1 and 0.958 (CI 0.861-0.995) for reader 2 with excellent inter-reader agreement (κ = 0.86). When the confidence level ratings of 1 or 2 were considered malignant thrombosis, the sensitivity, specificity, PPV, and NPV in differentiating malignant from benign thrombosis were 100%, 83%, 95%, and 100% for reader 1 and 100%, 92%, 97%, and 100% for reader 2. CONCLUSION: CEUS is useful to differentiate malignant and benign venous thrombosis associated with HCC with high diagnostic accuracy.

Assessment of colorectal hepatic metastases by quantitative T2 relaxation time.

AIM: To determine the T(2) relaxation time of colorectal hepatic metastases and changes in T(2) relaxation times following chemotherapy. MATERIALS AND METHODS: 42 patients with 96 hepatic colorectal metastases underwent baseline MRI. Axial T(1), T(2) and multi-echo GRASE sequences were acquired. ROIs were drawn on T(2) relaxation maps, obtained from GRASE images, encompassing metastasis and normal liver to record T(2) relaxation time values. In 11 patients with 28 metastases, MRI was repeated using same protocol at 6 weeks following chemotherapy. The median pre-treatment T(2) values of metastases and normal liver were compared using the Mann-Whitney test. The pre- and post-treatment median T(2) values of metastases were compared using the Wilcoxon-Rank test for responding (n=16) and non-responding (n=12) lesions defined by RECIST criteria. The change in T(2) values (ΔT(2)) were compared and correlated with percentage change in lesion size. RESULTS: There was no difference in the pre-treatment median T(2) of metastases between responding (67.3±8.6) and non-responding metastases (71.4±16.5). At the end of chemotherapy, there was a decrease in the median T(2) of responding lesions (61.6±12.6) p=0.83, and increase in non-responding lesions (76.2±18.4) p=0.03, but these were not significantly different from the pre-treatment values. There was no significant difference in ΔT(2) of responding and non-responding lesions (p=0.18) and no correlation was seen between size change and ΔT(2) (coefficient=0.3). CONCLUSION: T(2) relaxation time does not appear to predict response of colorectal liver metastasis to chemotherapy.